52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
FDA Expands Authorization Of Two Monoclonal Antibodies For Treatment Of Covid-19 To Younger Pediatric Patients, Including Newborns
Innovent Biologics Says PD-1 Inhibitor Tyvyt Successfully Included In Updated NDRL
Adage Capital Partners Raises Stake in Tesla, Merck, Takes In Moderna, Novavax
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.
Biotechnology & Drugs
Lilly Corporate Ctr
Drop Code 1094, Lilly Corporate Ctr
David A. Ricks
Chairman of the Board, President, Chief Executive Officer
Chief Financial Officer, Senior Vice President
Aarti S. Shah
Senior Vice President, Chief Information and Digital Officer
Daniel M. Skovronsky
Senior Vice President, Chief Scientific Officer, President, Lilly Research Laboratories
Melissa Stapleton Barnes
Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Europe crossed 75 million coronavirus cases according to a Reuters tally, as the region braces for the new Omicron variant at a time when hospitals in some countries are already strained by the current surge.
The U.S. Food and Drug Administration on Friday authorized the use of Eli Lilly's COVID-19 dual-antibody therapy in treating mild to moderate symptoms in all children, including newborns, who are at risk of severe illness.
AstraZeneca, Eli Lilly, Regeneron and GlaxoSmithKline are among the biggest pharmaceutical companies to have developed COVID-19 treatments using a class of drugs called monoclonal antibodies.
Eli Lilly and Co said on Tuesday that the U.S. government bought 614,000 additional doses of its COVID-19 antibody therapy for $1.29 billion.
Eli Lilly said on Tuesday it has started the application process for a U.S. approval of its closely watched experimental Alzheimer's drug and expects a regulatory decision by the second half of 2022, potentially setting it up against rival Biogen's recently approved Aduhelm.
The U.S. Food and Drug Administration said on Friday distribution of GlaxoSmithKline and Vir Biotechnology's antibody treatment for COVID-19 would be controlled by the government.
The European Commission has signed a joint procurement contract with U.S. drugmaker Eli Lilly and Co for the supply of a monoclonal antibody treatment for COVID-19, the EU executive arm said in a statement on Tuesday.
Eli Lilly on Tuesday announced a pact with the European Commission to supply up to 220,000 doses of its COVID-19 dual antibody cocktail to European countries for patients aged 12 years and older who are at a high risk of progressing to severe disease.
Eli Lilly on Tuesday announced a pact with the European Commission (EC) to supply up to 220,000 doses of its COVID-19 dual antibody cocktail for patients aged 12 years and older who are at a high risk of progressing to severe disease. (Reporting by Manojna Maddipatla in...
Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, etesevimab.
Eli Lilly and Co was accused in a proposed class action filed on Wednesday of systematically refusing to interview and hire older workers for sales representative jobs, opting instead to target millennials and recent college graduates.
U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies. The Department of Health...
Regeneron Pharmaceuticals Inc on Thursday blew past analysts' estimates for second-quarter profit and revenue and said it has seen a recent uptick in the use of its COVID-19 therapy by patients in the United States.
U.S. stocks rose, 10-year Treasuries were flat and oil prices fell on Tuesday as markets weighed mixed signals from corporate earnings and economic growth data.
Eli Lilly and Co and partner Incyte Corp said on Tuesday additional results from a late-stage study showed their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.
The European Commission on Tuesday picked four antibody treatments and a repurposed rheumatoid arthritis drug by Eli Lilly for an initial portfolio of preferred drugs to treat COVID-19.
U.S. health officials on Friday paused the distribution of Eli Lilly's COVID-19 antibody cocktail therapy as it failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.
Eli Lilly and Co said it will seek accelerated approval from the U.S. health regulator this year for its Alzheimer's candidate, weeks after a rival drug from Biogen Inc won the agency's endorsement using the same regulatory pathway.
The U.S. health regulator authorized a lower dose of Regeneron Pharmaceutical's COVID-19 antibody cocktail that can be given by injection, a move that could ease logistical challenges stemming from administering a higher dose intravenously.
Eli Lilly and Co's antibody drug combination has received an emergency use approval in India for the treatment of mild-to-moderate COVID-19, bolstering the country's arsenal of medicines to tackle a devastating second wave of the pandemic.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.